Collaborate Drug Discovery Inc.The landscape of macromolecule drug discovery is evolving rapidly, with oligonucleotides and peptides leading the way in innovative therapeutic applications. CDD Vault, a leading scientific data management system, significantly improves the way researchers manage macromolecule data by introducing a dedicated Macromolecule mode that seamlessly integrates with modern workflows.
Tenthpin GroupThe much-discussed digital transformation in the healthcare sector is in full swing. European Biotechnology spoke with Dr. Sabrina Graf, COO of the globally active Tenthpin Group, about how the right software can improve quality management, keep the system landscape lean, and safe both, time and money.
Wilfried Le Goff (INSERM, Sorbonne Université)Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.
SLASThe Society for Laboratory Automation & Screening (SLAS) has selected the European Biotechnology Magazine as its official media partner.
SLAS - Alexandra Csuport PhotographyNew AI tools and drug screening based on human cells and organoids promise a quantum leap in the success rate of drug development and in the processing of data from high-throughput analyses as well as a revolution in diagnostics. The SLAS Europe 2024 conference in Barcelona highlighted the latest advances set to transform the entire biopharma sector.
EuroscreenFastThe study of G protein-coupled receptor (GPCR) signalling is crucial for understanding a wide range of physiological processes. Among the methods used to monitor calcium signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.
BIOCOMMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles are now hitting markets and pipelines. A range of bispecific antibodies and antibody-drug conjugates – along with CAR-Ts, TCR-RTs and NK cell-based immunoreceptor constructs – were in focus at the PEGS Europe Summit.
VALIDOGENRecombinant protein production in Pichia typically relies on AOX1 promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.
Tebubio SASMessenger RNA (mRNA) has gained significant attention since being used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. mRNA holds potential for preventing and treating many difficult-to-treat or genetic diseases, including cancers. However, its production is complex and raises challenges for researchers developing new therapies: Discover Tebubio.
Jeremy Levin, Ovid TherapeuticsThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.